FDA rewrites its guidance on studying drug doses in liver-impaired patients

The liver clears a large share of the drugs people take, so how a medicine behaves in someone whose liver is damaged is a routine but consequential question — it often determines whether the standard dose is safe. On 2 September the Food and Drug Administration announced a draft guidance that updates how drug developers are expected to study that question [s1].

The document is a draft "guidance for industry," which is worth defining. FDA guidances are not regulations; they describe the agency's current thinking and are non-binding on both sponsors and FDA. Their influence is practical rather than legal: they set the expectations a drug company plans its studies around. This one is titled "Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage," and the notice announces its availability for comment [s1].

What is changing

The draft assists sponsors in the design and analysis of studies that assess the influence of hepatic impairment on the pharmacokinetics — and, where appropriate, the pharmacodynamics — of a drug, including therapeutic biological products [s1].

Two words there mark the update. "Pharmacodynamics" means the guidance reaches beyond how much drug ends up in the blood (pharmacokinetics) to what the drug does to the body, where appropriate. And "including therapeutic biological products" brings biologics — the large-molecule drugs that have come to dominate new approvals — explicitly into scope [s1].

What it replaces

The draft comes with a housekeeping action that dates the old approach. FDA is simultaneously withdrawing an earlier guidance, "Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling," issued in May 2003, which formerly provided recommendations on including hepatic-impairment information in labeling [s1].

A guidance in place since 2003 predates much of the modern biologics era, so replacing it is less a reversal than a catch-up. The notice frames the new draft as FDA's current thinking once finalised [s1], which is the standard language signalling that the 2003 text no longer reflects how the agency wants these studies done.

Why the liver question is hard

The reason a dedicated guidance exists at all is that hepatic impairment is not one thing. A liver can be mildly, moderately or severely compromised, and the degree changes how much of a drug is cleared and how much accumulates. Studying it well means enrolling patients across those categories and measuring what actually happens to drug levels — and, the new draft adds, what the drug does at those levels, where relevant [s1]. That is harder than it sounds: patients with liver disease often have other organs affected too, and separating the liver's contribution from everything else is the methodological problem the guidance exists to standardise.

Biologics sharpen the issue. Large-molecule drugs are not cleared by the liver the way small-molecule pills are, so the assumptions baked into a 2003 document written largely around conventional drugs do not transfer cleanly [s1]. Bringing therapeutic biological products explicitly into scope is the draft's acknowledgement that the science of the intervening two decades outgrew the old text.

What happens next

This is a draft, and the notice invites comment before FDA begins work on the final version [s1]. That sequencing matters: the window to influence the final expectations is now, while the text is still labelled draft. Comments submitted to the public docket are posted, and the notice sets out how to submit them, including a separate route for confidential information [s1].

None of this carries the force of law. A guidance describes what FDA currently expects and how it intends to exercise judgement; sponsors can, in principle, take a different, justified approach. But in practice the expectations a guidance sets are the path of least resistance through review, which is why a revision of a long-standing one is worth noting even though it changes no rule.

For patients, nothing changes today — no dose is altered by a guidance about how to design studies. The downstream effect, if any, is slower and indirect: clearer expectations for hepatic-impairment studies feed into the dosing instructions that eventually appear on drug labels, particularly for biologics that the 2003 guidance did not squarely address.

This article describes a draft regulatory guidance and does not offer medical advice.

Sources

• Pharmacokinetics in Patients With Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosage; Draft Guidance for Industry; Availability, Food and Drug Administration (Federal Register), 2 September 2026